Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Approximately 80% of patients with hepatocellular carcinoma (HCC) experience recurrence within five years after surgery. Currently, there is no standard protocol for the application of neoadjuvant therapy in HCC, but neoadjuvant immunotherapy has been shown to influence the survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Mei, Chen, Shanwen, Li, Conggui, Du, Yingying, Li, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913451/
https://www.ncbi.nlm.nih.gov/pubmed/36765557
http://dx.doi.org/10.3390/cancers15030600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913451/
https://www.ncbi.nlm.nih.gov/pubmed/36765557
http://dx.doi.org/10.3390/cancers15030600

Ejemplares similares